Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

We were very pleased that the private placement was supported by existing investors and our Board of Directors, all of whom participated in this financing,” said Samir R. Patel, MD, President and CEO ...

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs ...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Oqory’s planned reverse merger with fellow antibody-drug conjugate (ADC) company Vincerx Pharma has fallen apart at the last ...

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables the precise functionalization of peptides and proteins.

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables ...